1. Investment Snapshot

2. Thesis

3. Valuation & Price Target

4. Business & Product Moat

5. People & Governance

6. Market & Macro

7. Financial Quality

8. Risk Register

9. Prediction Market

10. 𝕏 Posts

Discussion

Mobia Medical, Inc. (MOBI) IPO | IPOSignal

Sections

1. Investment Snapshot

2. What does Mobia Medical, Inc. do?

3. Valuation

4. Business & Product Moat

5. People & Governance

6. Financial Quality

Discussion

Inline comments

Investment Snapshot

What does Mobia Medical, Inc. do?

Valuation

Business & Product Moat

People & Governance

Financial Quality

Discussion

Mobia Medical, Inc.

Analyst research, target price, syndicate analytics, and valuation sections are included with an active subscription. View plans

Investment Snapshot

424B4 All Filings

Symbol

MOBI

Event Date

2026-05-08

Sector

Health Care

Subsector

Health Care Equipment & Supplies

Offer Range

—

Shares Offered

10M

Total Shares Post-IPO

33.25M

Market Cap

—

Target Price

$00.00

Implied Upside vs Midpoint

$00.00

Description

**Valuation Verdict:** At the $15 midpoint, Mobia screens expensive at ~15.5x 2025 sales ($32.0M), leaving little margin for error in a single‑product story where reimbursement and controls remediation can drive (or derail) adoption. **Catalyst Timeline:** The next leg is payer conversion from “experimental” to reimbursed status; discrete coverage decisions and evidence readouts that support reimbursement are the clearest near‑term re‑rating catalysts, with implant volume trends as the confirming signal. **Growth & Margin Trajectory:** Revenue nearly doubled from $15.6M (2024) to $32.0M (2025) and gross profit reached $25.98M (~81% gross margin), but operating losses widened to $(46.4)M as commercialization spending ramped, keeping the model dependent on continued access to capital. **Governance & Operational Risk:** Risk is concentrated in limited coverage, single‑product exposure, and a disclosed material weakness in internal controls, each of which can slow uptake, raise financing costs, or force dilution. **Scenario Targets:** Target price: $15.00 with implied upside/downside vs offer midpoint: $0; the base case requires visible reimbursement momentum and sustained procedure growth to defend the current sales multiple, while a coverage stall would likely drive multiple compression.

Mobia Medical (proposed ticker MOBI) is an early commercial medtech company marketing the FDA‑approved Vivistim Paired VNS system for post‑stroke upper‑limb rehabilitation.

○

Product: Vivistim Paired VNS, an implanted IPG with lead and clinician software; FDA PMA (2021).

○

Commercial stage with a direct salesforce and market access team.

○

180‑day lockup.

What does Mobia Medical, Inc. do?

Valuation Verdict

At the $15 midpoint, Mobia screens expensive at ~15.5x 2025 sales ($32.0M), leaving little margin for error in a single‑product story where reimbursement and controls remediation can drive (or derail) adoption.

Catalyst Timeline

The next leg is payer conversion from “experimental” to reimbursed status; discrete coverage decisions and evidence readouts that support reimbursement are the clearest near‑term re‑rating catalysts, with implant volume trends as the confirming signal.

Growth & Margin Trajectory

Revenue nearly doubled from $15.6M (2024) to $32.0M (2025) and gross profit reached $25.98M (~81% gross margin), but operating losses widened to $(46.4)M as commercialization spending ramped, keeping the model dependent on continued access to capital.

Governance & Operational Risk

Risk is concentrated in limited coverage, single‑product exposure, and a disclosed material weakness in internal controls, each of which can slow uptake, raise financing costs, or force dilution.

Scenario Targets

Target price: $15.00 with implied upside/downside vs offer midpoint: $0; the base case requires visible reimbursement momentum and sustained procedure growth to defend the current sales multiple, while a coverage stall would likely drive multiple compression.

Mobia is a high‑risk medtech tied to one central variable: whether payer coverage broadens enough to unlock scaled hospital adoption. PMA approval and early traction support the opportunity, but the underwriting case depends on converting payors from investigational to covered status and sustaining implant growth while building outcomes evidence that keeps reimbursement durable.

○

Large addressable U.S. population cited (~1M chronic ischemic stroke survivors with moderate‑to‑severe impairment).

○

Revenue roughly doubled from 2024 to 2025, consistent with early commercial uptake.

○

The primary remaining hurdles are coverage, commercial scale, and evidence generation.

Valuation

████████████████████

At the $15 midpoint, Mobia implies ~15.5x price sales on 2025 revenue of $32.0M. For a single‑product, reimbursement‑dependent story with a disclosed control weakness, that multiple effectively requires sustained rapid growth plus tangible payer progress; absent coverage wins, the downside is more likely to show up as multiple compression than a slow grind in fundamentals.

○

Implied P S (pro forma) ≈ 15.5x on 2025 revenue $32.0M.

Business & Product Moat

████████████████████

People & Governance

Management includes experienced medtech commercial leadership and investor representation on the board. The founder stepping down pre‑IPO reduces founder concentration but creates execution risk during the handoff. The disclosed material weakness in internal control raises the bar for the finance function and audit committee until remediation is proven.

○

CEO Richard Foust — CEO since Jan 2022.

○

CFO Nelson Bunker Curnes; material weakness flagged in the filing.

○

Board chaired by Dana G. Mead, Jr., with multiple healthcare public‑company board experiences.

Financial Quality

2025 gross margin ≈ 81.2%.

Mobia grew revenue from $15.6M (2024) to $32.0M (2025) and generated $25.98M of gross profit in 2025, supporting attractive gross unit economics. Operating losses widened to (46.4)M in 2025 as the company invested in commercialization, so investors should expect ongoing burn until growth translates into operating leverage.

Risks

−

Operating loss: (24.2)M (2024) → (46.4)M (2025).

Observations

○

Revenue: $15.6M (2024) → $32.0M (2025).

○

Gross profit: $12.45M (2024) → $25.98M (2025).

○

Cash & equivalents: $14.6M (2024) → $33.6M (2025).